Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 13Urinary Bladder Neoplasms 11Ovarian Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Neoplasm Metastasis 5Colorectal Neoplasms 5Cholangiocarcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Lymphoma, Large B-Cell, Diffuse 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Recurrence 2Rectal Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Gallbladder Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urologic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Gemcitabine × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡